461 related articles for article (PubMed ID: 25561537)
21. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
23. Clofazimine protects against Mycobacterium tuberculosis dissemination in the central nervous system following aerosol challenge in a murine model.
Baijnath S; Moodley C; Ngcobo B; Singh SD; Kruger HG; Arvidsson PI; Naicker T; Pym A; Govender T
Int J Antimicrob Agents; 2018 Jan; 51(1):77-81. PubMed ID: 28843822
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models.
Li SY; Irwin SM; Converse PJ; Mdluli KE; Lenaerts AJ; Nuermberger EL
Antimicrob Agents Chemother; 2015 Jul; 59(7):4026-30. PubMed ID: 25918146
[TBL] [Abstract][Full Text] [Related]
25. Statin adjunctive therapy shortens the duration of TB treatment in mice.
Dutta NK; Bruiners N; Pinn ML; Zimmerman MD; Prideaux B; Dartois V; Gennaro ML; Karakousis PC
J Antimicrob Chemother; 2016 Jun; 71(6):1570-7. PubMed ID: 26903278
[TBL] [Abstract][Full Text] [Related]
26. Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.
Liu Y; Pertinez H; Davies GR; Gillespie SH; Coates AR; Hu Y
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661869
[TBL] [Abstract][Full Text] [Related]
27. Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
Liu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Harrison T; Davies G; Coates A; Hu Y
J Antimicrob Chemother; 2018 Mar; 73(3):724-731. PubMed ID: 29244108
[TBL] [Abstract][Full Text] [Related]
28. Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis.
Xu J; Tasneen R; Peloquin CA; Almeida DV; Li SY; Barnes-Boyle K; Lu Y; Nuermberger E
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038265
[TBL] [Abstract][Full Text] [Related]
29. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.
Nuermberger EL; Yoshimatsu T; Tyagi S; Williams K; Rosenthal I; O'Brien RJ; Vernon AA; Chaisson RE; Bishai WR; Grosset JH
Am J Respir Crit Care Med; 2004 Nov; 170(10):1131-4. PubMed ID: 15306535
[TBL] [Abstract][Full Text] [Related]
30. Activity of linezolid-containing regimens against multidrug-resistant tuberculosis in mice.
Zhao W; Guo Z; Zheng M; Zhang J; Wang B; Li P; Fu L; Liu S
Int J Antimicrob Agents; 2014 Feb; 43(2):148-53. PubMed ID: 24290060
[TBL] [Abstract][Full Text] [Related]
31. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens.
Daniel N; Lounis N; Ji B; O'Brien RJ; Vernon A; Geiter LJ; Szpytma M; Truffot-Pernot C; Hejblum G; Grosset J
Am J Respir Crit Care Med; 2000 May; 161(5):1572-7. PubMed ID: 10806157
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: a clinical trial.
Zheng X; Gui X; Yao L; Ma J; He Y; Lou H; Gu J; Ying R; Chen L; Sun Q; Liu Y; Ho CM; Lee BY; Clemens DL; Horwitz MA; Ding X; Hao X; Yang H; Sha W
Emerg Microbes Infect; 2023 Dec; 12(1):2187247. PubMed ID: 36872899
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
[TBL] [Abstract][Full Text] [Related]
34. Identifying Regimens Containing TBI-166, a New Drug Candidate against
Zhang Y; Zhu H; Fu L; Wang B; Guo S; Chen X; Liu Z; Huang H; Yang T; Lu Y
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061157
[TBL] [Abstract][Full Text] [Related]
35. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.
De Groote MA; Gilliland JC; Wells CL; Brooks EJ; Woolhiser LK; Gruppo V; Peloquin CA; Orme IM; Lenaerts AJ
Antimicrob Agents Chemother; 2011 Mar; 55(3):1237-47. PubMed ID: 21135176
[TBL] [Abstract][Full Text] [Related]
36. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.
Dhillon J; Dickinson JM; Sole K; Mitchison DA
Antimicrob Agents Chemother; 1996 Mar; 40(3):552-5. PubMed ID: 8851569
[TBL] [Abstract][Full Text] [Related]
37. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.
Dutta NK; Illei PB; Peloquin CA; Pinn ML; Mdluli KE; Nuermberger EL; Grosset JH; Karakousis PC
Antimicrob Agents Chemother; 2012 Jul; 56(7):3726-31. PubMed ID: 22547623
[TBL] [Abstract][Full Text] [Related]
38. Shortened tuberculosis treatment regimens: what is new?
Silva DR; Mello FCQ; Migliori GB
J Bras Pneumol; 2020; 46(2):e20200009. PubMed ID: 32215450
[TBL] [Abstract][Full Text] [Related]
39. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
Lounis N; Veziris N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
Antimicrob Agents Chemother; 2006 Nov; 50(11):3543-7. PubMed ID: 16954317
[TBL] [Abstract][Full Text] [Related]
40. Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility.
Lee BY; Clemens DL; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ho CM; Horwitz MA
PLoS One; 2018; 13(11):e0207469. PubMed ID: 30427938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
